These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26032946)

  • 1. The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance.
    Bahri P; Dodoo AN; Edwards BD; Edwards IR; Fermont I; Hagemann U; Hartigan-Go K; Hugman B; Mol PG
    Drug Saf; 2015 Jul; 38(7):621-7. PubMed ID: 26032946
    [No Abstract]   [Full Text] [Related]  

  • 2. The role and strategy of ISoP in global pharmacovigilance.
    Olsson S; Harrison-Woolrych M
    Int J Clin Pharm; 2018 Aug; 40(4):740-743. PubMed ID: 30073610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electronic Reporting Systems in Pharmacovigilance: The Implementation of VigiFlow in Brazil.
    Vogler M; Ricci Conesa H; de Araújo Ferreira K; Moreira Cruz F; Simioni Gasparotto F; Fleck K; Maciel Rebelo F; Kollross B; Silveira Gonçalves Y
    Pharmaceut Med; 2020 Oct; 34(5):327-334. PubMed ID: 32930977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Communication in drug safety: a report from an interactive debate held at the 10th annual meeting of the international society of pharmacovigilance (ISoP), 2010.
    Bahri P; Mol PG; Théophile H; Edwards IR; Hugman BP
    Drug Saf; 2011 Oct; 34(10):881-2. PubMed ID: 21879782
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacovigilance Discussion Forum--The European Generic Medicines Association's 8th Annual Meeting (January 21, 2015--London, UK).
    Lam S
    Drugs Today (Barc); 2015 Jan; 51(1):89-92. PubMed ID: 25685861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacovigilance in Europe.
    Johnson CL; Hutchinson JA
    Transplantation; 2015 Aug; 99(8):1542-3. PubMed ID: 26308299
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data.
    Solomon C; Gröner A; Ye J; Pendrak I
    Thromb Haemost; 2015 Apr; 113(4):759-71. PubMed ID: 25502954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacovigilance and use of online health information.
    Masoni M; Guelfi MR; Conti A; Gensini GF
    Trends Pharmacol Sci; 2013 Jul; 34(7):357-8. PubMed ID: 23759353
    [No Abstract]   [Full Text] [Related]  

  • 9. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Causality assessment in pharmacovigilance: The French method and its successive updates.
    Miremont-Salamé G; Théophile H; Haramburu F; Bégaud B
    Therapie; 2016 Apr; 71(2):179-86. PubMed ID: 27080836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Problems encountered in the pharmacovigilance of violence and aggression.
    Prescrire Int; 2014 Jun; 23(150):154. PubMed ID: 25121149
    [No Abstract]   [Full Text] [Related]  

  • 12. [Plan of action for improving medicinal drug safety].
    Sommer H; Dwenger A
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(10):707-8. PubMed ID: 23217721
    [No Abstract]   [Full Text] [Related]  

  • 13. The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review.
    Dias P; Penedones A; Alves C; Ribeiro CF; Marques FB
    Curr Drug Saf; 2015; 10(3):234-50. PubMed ID: 26219291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drugs and indications in 2014. Some advances this year, but many drugs are poorly evaluated, too expensive, or more dangerous than useful.
    Prescrire Int; 2015 Apr; 24(159):107-10. PubMed ID: 25941710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are consumers ready to take part in the Pharmacovigilance System?--a Portuguese preliminary study concerning ADR reporting.
    Matos C; van Hunsel F; Joaquim J
    Eur J Clin Pharmacol; 2015 Jul; 71(7):883-90. PubMed ID: 26004569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Asian Pharmacoepidemiology Network (AsPEN): promoting multi-national collaboration for pharmacoepidemiologic research in Asia.
    ; Andersen M; Bergman U; Choi NK; Gerhard T; Huang C; Jalbert J; Kimura M; Kimura T; Kubota K; Lai EC; Ooba N; Park BJ; Pratt N; Roughead EE; Sato T; Setoguchi S; Shin JY; Sundström A; Yang YH
    Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):700-4. PubMed ID: 23653370
    [No Abstract]   [Full Text] [Related]  

  • 18. Is pharmacovigilance of biologicals cost-effective?
    Claus B
    Int J Clin Pharm; 2018 Aug; 40(4):787-789. PubMed ID: 30051230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Encouraging spontaneous reporting of adverse effects.
    Prescrire Int; 2015 Feb; 24(157):53. PubMed ID: 25802925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adverse drug reaction - Definitions, risk factors and pharmacovigilance].
    Krähenbühl S
    Ther Umsch; 2015 Dec; 72(11-12):669-71. PubMed ID: 26654809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.